The estimated Net Worth of Michael David Smith is at least $80.4 millier dollars as of 1 June 2021. Mr. Smith owns over 7,500 units of KalVista Pharmaceuticals Inc stock worth over $80,400 and over the last 4 years he sold KALV stock worth over $0. In addition, he makes $0 as Senior Vice President - Development at KalVista Pharmaceuticals Inc.
Michael has made over 2 trades of the KalVista Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of KALV stock worth $62,925 on 1 June 2021.
The largest trade he's ever made was exercising 10,014 units of KalVista Pharmaceuticals Inc stock on 28 April 2021 worth over $84,017. On average, Michael trades about 2,919 units every 6 days since 2020. As of 1 June 2021 he still owns at least 7,500 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Michael D. Smith serves as Senior Vice President - Development of the Company. He served as the Vice President, Clinical Development of KalVista Limited since February 2016 and became our Vice President, Clinical Development as of November 2016, and was promoted to Senior Vice President, Development in May 2019. Prior to joining us, he was the Director, Scientific Affairs at PRA Health Sciences from July 2011 to February 2016. Prior to that, Dr. Smith worked as the Senior Manager, Clinical Development and Regulatory Affairs at ZARS Pharma. Dr. Smith also has served as an Adjunct Assistant Professor at the University of Utah since August 2014. Dr. Smith holds a B.Sc. from Brigham Young University and a Pharm.D. from the University of Utah.
Michael Smith is 41, he's been the Senior Vice President - Development of KalVista Pharmaceuticals Inc since 2019. There are 17 older and no younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... et Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: